BOSTON / May 23, 2023 / Business Wire / 908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming William Blair 43rd Annual Growth Stock Conference.
908 Devices’ management is scheduled to present on Wednesday, June 7 at 1:20 p.m. Central Time / 2:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.908devices.com.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.
| Last Trade: | US$6.70 |
| Daily Change: | -0.08 -1.18 |
| Daily Volume: | 217,126 |
| Market Cap: | US$240.260M |
May 13, 2025 April 30, 2025 March 04, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
